Scientists at Verve Therapeutics in Boston conducted the inaugural human trial of base editing, using the treatment VERVE-101 to deactivate the PCSK9 gene in the liver. The gene regulates ‘bad’ cholesterol, and the one-time injection resulted in a significant LDL reduction of up to 55%. This milestone suggests a potential transformative approach to treat coronary artery disease. However, safety concerns emerged, with two serious adverse events, including a death. The findings, presented at the American Heart Association meeting, indicate both promise and challenges for this ground-breaking gene-editing technique.
Related Posts
Using table salt regularly is associated with a 41% increased risk of gastric cancer
The article from Medical News Today discusses the link between high salt intake and an increased risk of stomach (gastric) cancer. Research indicates that adding salt to food, as well as consuming processed foods high in salt, can damage the stomach lining and lead to inflammation, ultimately raising the risk of gastric cancer. The harmful […]
IDENTIFYING PREDATORY JOURNALS
What are Predatory journals? Predatory journals also called fake, unreliable, and pseudo-journals are publications that misrepresent their publishing practices while claiming to be authentic scholarly journals. These are published by publishers that “produce counterfeit journals to abuse the open-access paradigm in which the author pays. These predatory publishers lack transparency and are dishonest. They […]
The Link Between Diabetic Microvascular Triopathy, Smoking, and Cardiovascular Risk
Recent research has shed light on the intricate relationship between diabetic microvascular triopathy (DMT), smoking, and the heightened risk of cardiovascular events. DMT, a condition affecting small blood vessels in individuals with diabetes, has long been recognized as a precursor to severe complications. However, emerging evidence suggests that smokers with diabetes face an even greater […]